Neurohypophyseal diabetes insipidus

Neurohypophyseal diabetes insipidus (NPI) is a rare endocrine disorder characterized by insufficient secretion of antidiuretic hormone (ADH) — vasopressin, which is synthesized in the hypothalamus and secreted in the neurohypophysis. In this disorder, excessive loss of water in the urine is observed, which leads to clinical manifestations such as polyuria and polydipsia. Unlike diabetes mellitus, NPI is not accompanied by an increase in plasma glucose levels. The etiology of the disease may be associated with both primary disorders in the hypothalamic-pituitary complex itself and with conditions that impair the synthesis or secretion of ADH. Different forms of the disease can vary in severity and clinical presentation, which makes its diagnosis and treatment challenging.

History of the disease and interesting historical facts

The history of studying neurohypophyseal diabetes insipidus goes back more than a century. The first mentions of a condition resembling NDI can be found in medical treatises of the late 19th and early 20th centuries. In 1911, researchers including S. T. Kuchera described polyneuropathic manifestations associated with impaired secretion of vasopressin. However, the precise definition and concept of NDI as a separate clinical condition were developed only in 1957 thanks to the work of R. A. Barth and M. H. Krepel. An important step in the study of the pathogenesis of NDI was the discovery of the mechanism of action of vasopressin and its effect on the kidneys. Modern technologies such as MRI and genetic testing have opened new horizons in understanding the causes of NDI and its various forms.

Epidemiology

The prevalence of neurohypophyseal diabetes insipidus is approximately 1-3 cases per 100,000 population. This pathology can manifest itself as a system, as a result of head trauma, neurosurgical interventions or as an independent endocrine disorder. It has been established that NPI is more common in adults and, according to estimates, the disease occurs slightly more often in men than in women. However, in some cases, its onset is noted already in childhood, which also requires additional attention and monitoring. Studies show that more than 50% cases are associated with traumatic injuries or tumors of the brain, especially in the hypothalamus and pituitary gland.

Genetic predisposition to this disease

There is evidence of a genetic predisposition to neurohypophyseal diabetes insipidus. Mutations in genes encoding components of the antidiuretic system have been identified in studies of various familial cases. One of the key genes involved in the etiology of NDI is the AVP gene, which codes for the synthesis of vasopressin. Some patients also have mutations in genes responsible for the function of aquaporins, especially AQP2, which impair water metabolism in the kidneys. Current genetic research is aimed at identifying other possible associated genes and mechanisms that may contribute to the development of NDI and its hereditary forms.

Risk factors for the development of this disease

Several factors may contribute to the development of neurohypophyseal diabetes insipidus. These factors are classified as physical, chemical, and related to the patient's medical history.

• Physical factors:
• Head injuries, especially in the area of the hypothalamus and pituitary gland;
• Neurosurgical interventions that result in damage to the structures that produce vasopressin;
• Brain tumors that put pressure on the hypothalamic-pituitary complex.
• Chemical factors:
• Exposure of the body to radioactive substances or toxic chemicals;
• Medicines such as lithium and some antipsychotics that can impair kidney function.
• Factors related to medical history:
• Diabetes mellitus as a concomitant endocrine disease;
• Vitamin D deficiency and other metabolic disorders.

Diagnosis of this disease

Diagnosis of neurohypophyseal diabetes insipidus is based on clinical manifestations, laboratory and instrumental studies. The main symptoms to pay attention to include:

• Polyuria is the excretion of a large volume of urine;
• Polydipsia - increased thirst;
• Decreased urine concentration, leading to hyponatremia and other electrolyte disturbances;
• Symptoms of dehydration such as dry skin and mucous membranes, weakness.

Laboratory tests include:

• General urine analysis to assess density and concentration;
• Blood biochemistry test to determine sodium and potassium levels;
• Measurement of serum vasopressin levels.

Radiological examinations such as MRI or CT play a significant role in identifying structural changes in the hypothalamic-pituitary complex. This could be a tumor, hemorrhage, trauma or other abnormalities.

An important aspect is the differential diagnosis, which allows distinguishing NDI from other forms of polyuria, such as Miller's diabetes and end-stage renal disease.

Treatment

Treatment of neurohypophyseal diabetes insipidus is aimed at replenishing the vasopressin deficiency and controlling the clinical manifestations of the disease. The main approaches are divided into pharmacological and surgical treatment.

General treatment includes:

• Lifestyle changes such as increasing fluid intake to reduce symptoms of dehydration;
• Monitoring electrolyte balance and correction of hyponatremia.

Pharmacological treatment consists of the administration of desmopressin, a synthetic analogue of vasopressin, which effectively helps to reduce polyuria and reduce thirst.

Surgical treatment may be indicated in the presence of tumors or other structural changes that affect the function of the hypothalamic-pituitary system.

Other treatments may include antidepressants or antipsychotics, which sometimes help control symptoms, although they are less specific in their effectiveness.

List of drugs used to treat this disease

Some of the drugs used to treat neurohypophyseal diabetes insipidus are:

• Desmopressin (Minirin);
• Repaglinide (for control of associated metabolic disorders);
• Asparkam (to correct electrolyte balance);
• Lithium (in rare cases, with concomitant conditions).

Disease monitoring

Monitoring of patients with neurohypophyseal diabetes insipidus includes regular checks of fluid status, electrolyte balance, and vasopressin levels. The prognosis for patients may vary depending on the cause and severity of the disease. Complications may include severe fluid and electrolyte imbalances, which may lead to serious conditions such as hyponatremia, with subsequent health consequences.

Age-related features of the disease

Neurohypophyseal diabetes insipidus can manifest itself at any age, but the nature of its course may vary. In children, the disease may be associated with hereditary factors or congenital anomalies of the hypothalamus structure. In older people, NDI is more likely to develop as a result of age-related changes or concomitant diseases.

Questions and Answers

• What is neurohypophyseal diabetes insipidus? Neurohypophyseal diabetes insipidus is an endocrine disorder caused by insufficient secretion of vasopressin, which leads to loss of fluid and electrolytes.
• How is NSD diagnosed? Diagnosis of NSD involves assessment of clinical symptoms, laboratory tests of urine and blood, and imaging of brain structures using MRI or CT.
• What drug is used to treat NSD? The main drug for the treatment of NDS is desmopressin, which effectively compensates for the deficiency of vasopressin.
• What are the main symptoms of NDS? The main symptoms of NDI include polyuria, polydipsia, hyponatremia and signs of dehydration.
• How does the course of the disease change with age? In children, the disease may be congenital, while in the elderly it may occur against the background of concomitant and age-related diseases.